Trial
NCT05751668
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
Phase IISUSPENDEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)
Condition
Anatomic Stage IV Breast Cancer AJCC v8
Intervention
Paclitaxel
Why stopped
Interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-02